ASCRS Continues to Push for Office Use Exemption in Senate Compounding Pharmacy Legislation

ASCRS continues to work with the American Academy of Ophthalmology to ensure the final version of S. 959, the Pharmaceutical Compounding Quality and Accountability Act, does not negatively impact ophthalmologists’ access to compounded products, such as biologics and other Food and Drug Administration (FDA) marketed drugs. As we have reported, the bill was originally introduced to address concerns over safety at compounding pharmacies in the wake of the deadly meningitis outbreak last fall. The bill would consolidate oversight of these pharmacies under the FDA and tighten access to compounded drugs to the point that physicians would not be permitted to stock compounded drugs in the office for emergent cases. The bill is now attached to another bill that establishes how the federal government tracks the movement of prescription medications in the supply chain to protect against the distribution of counterfeit or stolen drugs.
We will continue to keep you updated.
quoted from here